Hebgene Biopharma vicit in "MMXXII Sina Biomedicine Industry catena innovation Ranking" maxime sollicitus novum conatibus aurea Equo Award

In December XXX, MMXXII, in "MMXXII Sinis Biopharmaceutical Industry Innovation Excellentia List" erat publice nuntiatum ad ostium ceremonia de "secundi Sinis Biopharmaceutical Industria catena innovation et transformatio culmen." Jiangsu Hebgene Biopharmaceutical Co. Ltd. feliciter parta "aurum equum award" et agnita est "maxime vigilans emergentes inceptis 2022."

Hoc album est compilavit usura notitia ex variis fontibus, comprehendo novum medicamento investigationis et progressionem magna database, comprehensive medicamento database, et medicamentis Migration database. Lustrationes ab National "Maior nova medicamento creaturae" Special Project, ad iudicium criteria erant statutum per XII dimensiones, ut novae pharmacum peltas, technicae progressiones, orci necessitates et investigationis et progressionem investments. A Panel de Academicians et peritos deduxit video Conferentiarum, online suffragii, et ponderati comprehensive censibus eligere propernitas awards, Kunpeng awards, et aurea equum awards. Hoc album facta est a prominent award in agro innovation et transformatio in Biopharmaceutical industria.

Ut primum comitatu in regione ut dari per "medicamento productio permit" ad plenam - processus commissis productio de car - T cellula therapy, et genitorem in comprehensive, qualitas et faciens et gene (CQDMO) Services.

Hoc award non solum significat operam Garnered per Hebgene Biopharma est innovative promotiones sed etiam serves ut inspiratio pro ulterius breakthroughs in CQDMO agri. In futurum, Hebgene Biopharma erit permanere ad intendunt ad occasum industria signa, optimizing ministerium exempla, accelerans progressionem cellula therapy medicamentis et propellentibus magis ex his innovative therapies in foro.

Post tempus: MMXXIII - II - 00:00:00 XVII